| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Peter Tontonoz | Q62569518 |
| Anna C Calkin | Q64359190 | ||
| P2860 | cites work | Synthetic LXR ligand inhibits the development of atherosclerosis in mice | Q24530617 |
| LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor | Q24656186 | ||
| Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia | Q24657127 | ||
| Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha | Q24683359 | ||
| Reciprocal regulation of inflammation and lipid metabolism by liver X receptors | Q28202771 | ||
| An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha | Q28294042 | ||
| Cooperative NCoR/SMRT interactions establish a corepressor-based strategy for integration of inflammatory and anti-inflammatory signaling pathways | Q28512993 | ||
| Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE | Q28513193 | ||
| Non-redundant roles for LXRalpha and LXRbeta in atherosclerosis susceptibility in low density lipoprotein receptor knockout mice | Q28589168 | ||
| Atherosclerosis. the road ahead | Q29618972 | ||
| LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse | Q30491802 | ||
| The E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2. | Q33924208 | ||
| TGF-beta 1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify. | Q34145009 | ||
| Identification of macrophage liver X receptors as inhibitors of atherosclerosis | Q34154665 | ||
| Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver X receptor agonist in low-density lipoprotein receptor-deficient mice | Q36953485 | ||
| Differential anti-atherosclerotic effects in the innominate artery and aortic sinus by the liver X receptor agonist T0901317 | Q37145836 | ||
| TLR/MyD88 and liver X receptor alpha signaling pathways reciprocally control Chlamydia pneumoniae-induced acceleration of atherosclerosis | Q37196471 | ||
| T0901317, an LXR agonist, augments PKA-induced vascular cell calcification | Q37218460 | ||
| Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. | Q37470344 | ||
| Laminar shear stress up-regulates the expression of stearoyl-CoA desaturase-1 in vascular endothelial cells. | Q37470957 | ||
| Liver X receptor agonist T0901317 reduces atherosclerotic lesions in apoE-/- mice by up-regulating NPC1 expression | Q38287462 | ||
| Up-regulation of skeletal muscle LIM protein 1 gene by 25-hydroxycholesterol may mediate morphological changes of rat aortic smooth muscle cells | Q40197929 | ||
| Liver X receptor and retinoic X receptor agonists modulate the expression of genes involved in lipid metabolism in human endothelial cells. | Q40377173 | ||
| Oxidized LDL downregulates ATP-binding cassette transporter-1 in human vascular endothelial cells via inhibiting liver X receptor (LXR). | Q40385609 | ||
| Crosstalk between LXR and Toll-like Receptor Signaling Mediates Bacterial and Viral Antagonism of Cholesterol Metabolism | Q40622775 | ||
| Stearoyl-CoA desaturase inhibits ATP-binding cassette transporter A1-mediated cholesterol efflux and modulates membrane domain structure | Q40683418 | ||
| GW3965, a synthetic liver X receptor (LXR) agonist, reduces angiotensin II-mediated pressor responses in Sprague-Dawley rats | Q41586886 | ||
| Macrophage apoptosis in advanced atherosclerosis | Q41851126 | ||
| Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages | Q42435836 | ||
| Native LDL upregulation of ATP-binding cassette transporter-1 in human vascular endothelial cells | Q43852825 | ||
| Accumulation of foam cells in liver X receptor-deficient mice | Q44114728 | ||
| T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice | Q44314934 | ||
| Liver X receptor agonists suppress vascular smooth muscle cell proliferation and inhibit neointima formation in balloon-injured rat carotid arteries | Q44940978 | ||
| Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists | Q45147987 | ||
| LXR-activating oxysterols induce the expression of inflammatory markers in endothelial cells through LXR-independent mechanisms. | Q46019644 | ||
| Effect of macrophage overexpression of murine liver X receptor-alpha (LXR-alpha) on atherosclerosis in LDL-receptor deficient mice | Q46372670 | ||
| LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3Leiden mice: time course and mechanisms | Q46403400 | ||
| 7-ketocholesterol, a major oxysterol, promotes pi-induced vascular calcification in cultured smooth muscle cells | Q46499797 | ||
| The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation | Q46506824 | ||
| Induction of stearoyl-CoA desaturase protects human arterial endothelial cells against lipotoxicity | Q46560187 | ||
| Defective mer receptor tyrosine kinase signaling in bone marrow cells promotes apoptotic cell accumulation and accelerates atherosclerosis | Q46604235 | ||
| The effect of T0901317 on ATP-binding cassette transporter A1 and Niemann-Pick type C1 in apoE-/- mice | Q46626487 | ||
| Laminar shear stress regulates liver X receptor in vascular endothelial cells | Q46838363 | ||
| Liver X receptor activator downregulates angiotensin II type 1 receptor expression through dephosphorylation of Sp1 | Q81172881 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | atherosclerosis | Q12252367 |
| P304 | page(s) | 1513-1518 | |
| P577 | publication date | 2010-08-01 | |
| P1433 | published in | Arteriosclerosis, Thrombosis, and Vascular Biology | Q4797542 |
| P1476 | title | Liver x receptor signaling pathways and atherosclerosis | |
| P478 | volume | 30 |
| Q37418674 | 3,5,3'-Triiodo-L-Thyronine- and 3,5-Diiodo-L-Thyronine- Affected Metabolic Pathways in Liver of LDL Receptor Deficient Mice |
| Q49156822 | A novel small molecule liver X receptor transcriptional regulator, nagilactone B, suppresses atherosclerosis in apoE-deficient mice. |
| Q24316186 | ABCA12 regulates ABCA1-dependent cholesterol efflux from macrophages and the development of atherosclerosis |
| Q58123949 | Activation of NLRP3 Inflammasome Promotes Foam Cell Formation in Vascular Smooth Muscle Cells and Atherogenesis Via HMGB1 |
| Q37466848 | Activation of liver X receptor attenuates lysophosphatidylcholine-induced IL-8 expression in endothelial cells via the NF-κB pathway and SUMOylation. |
| Q54347900 | Activation of liver X receptor enhances the proliferation and migration of endothelial progenitor cells and promotes vascular repair through PI3K/Akt/eNOS signaling pathway activation. |
| Q36352141 | Activation of liver X receptor inhibits osteopontin and ameliorates diabetic nephropathy |
| Q34490950 | Altered gene expression pattern in peripheral blood mononuclear cells in patients with acute myocardial infarction |
| Q35903298 | Animal models of atherosclerosis |
| Q26860162 | Anti-inflammatory therapy in chronic disease: challenges and opportunities |
| Q30241977 | Association between familial hypobetalipoproteinemia and the risk of diabetes. Is this the other side of the cholesterol-diabetes connection? A systematic review of literature |
| Q42121513 | Blood cellular mutant LXR-α protein stability governs initiation of coronary heart disease |
| Q89835099 | Characterizing the Retinal Phenotype in the High-Fat Diet and Western Diet Mouse Models of Prediabetes |
| Q64965319 | Cholesterol metabolism-physiological regulation and pathophysiological deregulation by the endoplasmic reticulum. |
| Q37864394 | Control of nuclear receptor activities in metabolism by post-translational modifications |
| Q35917056 | Crosstalk between reverse cholesterol transport and innate immunity |
| Q37702199 | Current guidelines for high-density lipoprotein cholesterol in therapy and future directions. |
| Q33916075 | Decreased expression of liver X receptor-α in macrophages infected with Chlamydia pneumoniae in human atherosclerotic arteries in situ. |
| Q38848673 | Detection and treatment of atherosclerosis using nanoparticles |
| Q39469616 | Dietary ellagic acid attenuates oxidized LDL uptake and stimulates cholesterol efflux in murine macrophages |
| Q30412216 | Differential regulation of gene expression by LXRs in response to macrophage cholesterol loading |
| Q45162592 | Discovery of Highly Potent Liver X Receptor β Agonists. |
| Q21285000 | Diverse roles of macrophages in atherosclerosis: from inflammatory biology to biomarker discovery |
| Q40764658 | Drugs that reverse disease transcriptomic signatures are more effective in a mouse model of dyslipidemia |
| Q35653968 | Effects of High Fat Feeding and Diabetes on Regression of Atherosclerosis Induced by Low-Density Lipoprotein Receptor Gene Therapy in LDL Receptor-Deficient Mice |
| Q36322805 | Emerging role of liver X receptors in cardiac pathophysiology and heart failure |
| Q34518507 | Emerging roles for nuclear receptors in the pathogenesis of age-related macular degeneration |
| Q38752078 | Estimation of Interleukin-1β Promoter (-31 C/T and -511 T/C) Polymorphisms and Its Level in Coronary Artery Disease Patients |
| Q37619593 | Eyeballing cholesterol efflux and macrophage function in disease pathogenesis |
| Q38099536 | Genetics of HDL-C: a causal link to atherosclerosis? |
| Q36740921 | Genome-wide analysis of LXRα activation reveals new transcriptional networks in human atherosclerotic foam cells |
| Q37726678 | Hepatic nuclear corepressor 1 regulates cholesterol absorption through a TRβ1-governed pathway |
| Q34440353 | Histone deacetylase 9 represses cholesterol efflux and alternatively activated macrophages in atherosclerosis development |
| Q35107280 | Hyperglycemic Ins2AkitaLdlr⁻/⁻ mice show severely elevated lipid levels and increased atherosclerosis: a model of type 1 diabetic macrovascular disease |
| Q41921187 | IL-27-Induced Type 1 Regulatory T-Cells Produce Oxysterols that Constrain IL-10 Production. |
| Q34489752 | Identification of biological markers of liver X receptor (LXR) activation at the cell surface of human monocytes |
| Q34226831 | Identification of novel liver X receptor activators by structure-based modeling |
| Q47433840 | Inflammation-regulated mRNA stability and the progression of vascular inflammatory diseases. |
| Q58329651 | Influence of liver-X-receptor on tissue cholesterol, coenzyme Q and dolichol content |
| Q34551679 | Inhibiting DNA Methylation by 5-Aza-2'-deoxycytidine ameliorates atherosclerosis through suppressing macrophage inflammation. |
| Q38038125 | Inhibition of cholesterol absorption: targeting the intestine. |
| Q38633215 | Intestinal toxicity of the type B trichothecene mycotoxin fusarenon-X: whole transcriptome profiling reveals new signaling pathways |
| Q38631767 | KLF4 Regulation of Ch25h and LXR Mitigates Atherosclerosis Susceptibility |
| Q58765163 | Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer |
| Q34444310 | LIM-only protein FHL2 is a positive regulator of liver X receptors in smooth muscle cells involved in lipid homeostasis |
| Q91916968 | LXRs regulate features of age-related macular degeneration and may be a potential therapeutic target |
| Q38570304 | LXRα regulates macrophage arginase 1 through PU.1 and interferon regulatory factor 8. |
| Q54324443 | LXRβ activation increases intestinal cholesterol absorption, leading to an atherogenic lipoprotein profile. |
| Q61797279 | Lactobacillus mucosae DPC 6426 as a bile-modifying and immunomodulatory microbe |
| Q36931267 | Lipid droplet-associated proteins in atherosclerosis (Review). |
| Q30684049 | Lipid metabolism emerges as a promising target for malignant glioma therapy |
| Q88761261 | Lipid metabolism reprogramming and its potential targets in cancer |
| Q90604280 | Lipid rafts as a therapeutic target |
| Q30426995 | Liver LXRα expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice |
| Q33553493 | Liver X receptor gene polymorphisms in tuberculosis: effect on susceptibility |
| Q36410637 | Liver X receptor modulates diabetic retinopathy outcome in a mouse model of streptozotocin-induced diabetes |
| Q42394480 | Liver X receptors and atherosclerosis: it is not all cholesterol |
| Q28082452 | Liver X receptors at the intersection of lipid metabolism and atherogenesis |
| Q57117258 | Liver X receptors in lipid signalling and membrane homeostasis |
| Q24608256 | Liver x receptors in atherosclerosis and inflammation |
| Q36602809 | Macrophage Phenotype and Function in Different Stages of Atherosclerosis |
| Q90661189 | Macrophage miR-34a Is a Key Regulator of Cholesterol Efflux and Atherosclerosis |
| Q30371540 | Macrophage-independent regulation of reverse cholesterol transport by liver X receptors. |
| Q29617765 | Macrophages in the pathogenesis of atherosclerosis |
| Q35571915 | MiR-320a contributes to atherogenesis by augmenting multiple risk factors and down-regulating SRF |
| Q43849671 | Mitochondrial (dys)function and regulation of macrophage cholesterol efflux |
| Q26825337 | Mitochondrial function and regulation of macrophage sterol metabolism and inflammatory responses |
| Q41482082 | Modified low density lipoprotein stimulates complement C3 expression and secretion via liver X receptor and Toll-like receptor 4 activation in human macrophages. |
| Q38892782 | Modulation of Macrophage Gene Expression via Liver X Receptor α Serine 198 Phosphorylation. |
| Q37152902 | Modulation of cardiometabolic pathways in skin and serum from patients with psoriasis |
| Q35679745 | Molecular Interactions between NR4A Orphan Nuclear Receptors and NF-κB Are Required for Appropriate Inflammatory Responses and Immune Cell Homeostasis |
| Q38125279 | Molecular biology of atherosclerosis |
| Q35924658 | Nanoparticles containing a liver X receptor agonist inhibit inflammation and atherosclerosis |
| Q93052075 | New Insights on the Role of Lipid Metabolism in the Metabolic Reprogramming of Macrophages |
| Q37314961 | New roles of HDL in inflammation and hematopoiesis |
| Q42674175 | Nogo-B receptor deficiency increases liver X receptor alpha nuclear translocation and hepatic lipogenesis through an adenosine monophosphate-activated protein kinase alpha-dependent pathway |
| Q49922734 | Non-genomic effects of nuclear receptors: insights from the anucleate platelet. |
| Q35165186 | Nuclear receptors as therapeutic targets for Alzheimer's disease |
| Q28079661 | Nutrition, insulin resistance and dysfunctional adipose tissue determine the different components of metabolic syndrome |
| Q28390150 | Nutritional lipidomics: molecular metabolism, analytics, and diagnostics |
| Q38133807 | Oxysterols and redox signaling in the pathogenesis of non-alcoholic fatty liver disease. |
| Q33649595 | Oxysterols and their cellular effectors |
| Q28535030 | Parameter trajectory analysis to identify treatment effects of pharmacological interventions |
| Q36987659 | Poly(ADP-ribose) Polymerase 1 Represses Liver X Receptor-mediated ABCA1 Expression and Cholesterol Efflux in Macrophages |
| Q38261037 | Practical strategies for modulating foam cell formation and behavior |
| Q35167931 | Purple perilla extracts with α-asarone enhance cholesterol efflux from oxidized LDL-exposed macrophages |
| Q125637246 | RETRACTED ARTICLE: The myocardial infarction-associated transcript 2 inhibits lipid accumulation and promotes cholesterol efflux in oxidized low-density lipoprotein-induced THP-1-derived macrophages via inhibiting mitogen-activated protein kinase si |
| Q52965346 | RIP140 as a novel therapeutic target in the treatment of atherosclerosis. |
| Q38459399 | Regression of inflammation in atherosclerosis by the LXR agonist R211945: a noninvasive assessment and comparison with atorvastatin |
| Q93193771 | Retinal Vascular Abnormalities and Microglia Activation in Mice with Deficiency in Cytochrome P450 46A1-Mediated Cholesterol Removal |
| Q55311460 | Serum amyloid P component therapeutically attenuates atherosclerosis in mice via its effects on macrophages. |
| Q57072613 | Sterol Metabolism and Transport in Atherosclerosis and Cancer |
| Q37149077 | Susceptibility of podocytes to palmitic acid is regulated by stearoyl-CoA desaturases 1 and 2. |
| Q39039098 | Tannerella forsythia BspA increases the risk factors for atherosclerosis in ApoE(-/-) mice |
| Q37457211 | Tanshinone IIA suppresses cholesterol accumulation in human macrophages: role of heme oxygenase-1. |
| Q38121980 | Targeting SREBP-1-driven lipid metabolism to treat cancer |
| Q30486738 | The Concise Guide to PHARMACOLOGY 2013/14: nuclear hormone receptors |
| Q36937104 | The association of NR1H3 gene with lipid deposition in the pig. |
| Q53615353 | The liver X receptor agonist AZ876 protects against pathological cardiac hypertrophy and fibrosis without lipogenic side effects. |
| Q37071339 | The liver X receptor agonist TO901317 protects mice against cisplatin-induced kidney injury |
| Q33653635 | The macrophage LBP gene is an LXR target that promotes macrophage survival and atherosclerosis |
| Q35104236 | The mutual interplay of lipid metabolism and the cells of the immune system in relation to atherosclerosis |
| Q38762998 | The role of dyslipidemia in diabetic retinopathy |
| Q37367993 | The role of the liver X receptor in chronic obstructive pulmonary disease |
| Q99616858 | Thrombin-Par1 signaling axis disrupts COP9 signalosome subunit 3-mediated ABCA1 stabilization in inducing foam cell formation and atherogenesis |
| Q33672543 | Transcriptional control of hepatic lipid metabolism by SREBP and ChREBP. |
| Q42774938 | Transcriptome profiling reveals that the SM22α-regulated molecular pathways contribute to vascular pathology |
| Q38161749 | Tumor metabolism of malignant gliomas |
| Q33879659 | Why AMD is a disease of ageing and not of development: mechanisms and insights |
| Q38916069 | miR-206 controls LXRα expression and promotes LXR-mediated cholesterol efflux in macrophages |
| Q55524753 | miR-33 inhibition attenuates the effect of liver X receptor agonist T0901317 on expression of liver X receptor alpha in mice liver. |
Search more.